AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Corbus MACD and KDJ Death Crosses Triggered on 15min Chart
ByAinvest
Thursday, Oct 2, 2025 12:34 pm ET1min read
Corbus's 15-minute chart has triggered a MACD Death Cross and KDJ Death Cross as of 10/02/2025 at 12:30. This indicates that the stock price is susceptible to further declines and the momentum is shifting towards a downward trajectory.
Corbus Pharmaceuticals (NASDAQ: CRBP) stock experienced a significant technical setback as of October 2, 2025, at 12:30, with the 15-minute chart indicating a MACD Death Cross and KDJ Death Cross. This development suggests a potential downward trend in the stock price, signaling a shift in momentum [1].Analysts have also shown caution towards Corbus' stock. Oppenheimer lowered its price target to $53.00 from $60.00, while maintaining an Outperform rating. This adjustment comes ahead of Corbus' presentation at the European Society for Medical Oncology (ESMO) conference, where the company will discuss results from approximately 100 additional patients treated with its Nectin-4 targeting ADC, CRB-701 [1].
Corbus is set to present data on CRB-701 at the ESMO conference, with a key opinion leader event scheduled for October 19, 2025, focusing on head and neck squamous cell carcinoma (HNSCC) and cervical cancer patients. The presentation is expected to strengthen both safety and efficacy datasets for CRB-701 [1].
Additionally, Corbus received an FDA Fast Track Designation for CRB-701, which is intended for treating recurrent or metastatic head and neck squamous cell carcinoma. Mizuho reiterated its Outperform rating for Corbus, maintaining a price target of $32.00. Corbus will also present updated clinical data from its Phase 1/2 study of CRB-701 at the ESMO Congress in October 2025, covering results from trials involving patients with urothelial and non-urothelial solid tumors [1].
Corbus has initiated the multiple ascending dose portion of its Phase 1 trial for CRB-913, aimed at treating obesity. This phase follows the single ascending dose portion completed earlier in the year, with no treatment-related neuropsychiatric events reported [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet